Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Contract Research

Cortex reports research results on use of ampakines CX1739 and CX717 to treat respiratory disorders Cortex Pharmaceuticals (CORX) announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease.
Contract Research & Services > Contract Research > News
Aquinox completes patient enrollment in Phase II trial of AQX-1125 to treat atopic dermatitis By PBR Staff Writer
Canada-based Aquinox Pharmaceuticals has completed patient enrolment in the Phase II KINSHIP trial of its lead drug candidate, AQX-1125, to treat atopic dermatitis.
Contract Research & Services > Contract Research > News Kadmon begins second Phase II trial of KD026 to treat type 2 diabetes By PBR Staff Writer
US-based biopharmaceutical firm Kadmon has started dosing in its second Phase II clinical trial (Study KD026-201) of its inhibitor of microsomal triglyceride transfer protein (MTP), KD026, in combination with metformin to treat patients with type 2 diabetes mellitus.
Contract Research & Services > Contract Research > News
See more Contract Research news

Latest Contract Research News and Insight

View all Contract Research news or find news targeted to your interests
Constellation begins Phase I trial of CPI-1205 in lymphoma patients
By PBR Staff Writer
US-based Constellation Pharmaceuticals has started a Phase I clinical trial of CPI-1205, a new inhibitor of Enhancer of Zeste Homolog 2 (EZH2), in patients with previously treated and progressive lymphomas.
Contract Research & Services > Contract Research > News
Co-D Therapeutics gets FDA orphan drug status for triolimus to treat angiosarcoma
Co-D Therapeutics, a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, announced that the US Food and Drug Administration (FDA) has granted Co-D's request for orphan drug designation of Triolimus for the treatment of the highly lethal malignancy, angiosarcoma.
Contract Research & Services > Contract Research > News
Merrimack completes NDA submission to FDA for cancer drug candidate MM-398
By PBR Staff Writer
Merrimack Pharmaceuticals has completed the rolling submission of the new drug application (NDA) to the US Food and Drug Administration (FDA) for MM-398 (irinotecan liposome injection), also called 'nal-IRI', to treat post-gemcitabine metastatic pancreatic cancer.
Contract Research & Services > Contract Research > News
Diagnostic Research Program Success
Non-invasive screening for fetal aneuploidy: a new maternal plasma marker.
Contract Research & Services > Contract Research > Case Studies
PRA's Unique Model Leads to Client Satisfaction - Project Team Uses Innovation and Flexibility to Overcome Challenges
A randomized, double-blind, placebo-controlled, Phase II study evaluating the ecacy and safety of Study Drug A in combination with Study Drug B administered as first-line treatment to subjects with unresectable, locally advanced, or metastatic pancreatic adenocarcinoma.
Contract Research & Services > Contract Research > Case Studies
PRA's Feasibility Leads to Unique Enrollment Strategy
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial. It was estimated that there may only be 1,000 to 3,000 patients in the US and Europe with the condition.
Contract Research & Services > Contract Research > Case Studies
PRA's Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the e cacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed partial epilepsy.
Contract Research & Services > Contract Research > Case Studies
Challenging Study Timeline Goals Achieved in Global Post-Authorization Safety Study (Pass)
A global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant. The first study was designed to generate data on the effectiveness of the study drug to reduce the risk of stroke in patients with atrial fibrillation. The second study was designed to collate data from patients treated for an acute deep vein thrombosis with either the study drug or Standard of Care. Both studies investigated the bleeding risk associated with the study drug.
Contract Research & Services > Contract Research > Case Studies
PRA Delivers Study Start-Up Success
A Phase IIa randomized double-blind, placebo-controlled, multi-center study to evaluate the ecacy, safety, and tolerability of of Study Drug when given Methotrexate (MTX) to subjects with active rheumatoid arthritis (RA) who have had an inadequate response to conventional disease-modifying anti-rheumatic drug therapy (DMARD).
Contract Research & Services > Contract Research > Case Studies
PRA Optimal Recruitment Strategies Reduce Enrollment Timelines
A Phase III trial comparing drug treatments in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant.
Contract Research & Services > Contract Research > Case Studies
View all Contract Research news or find news targeted to your interests